Membranous Nephropathy

Primer on Kidney Diseases

Volumn , Issue , 2009, Pages 170-178

  Cattran, Daniel C ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 83155186610     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-5185-5.00019-5     Document Type: Chapter

References (26)

1. E. Alexopoulos, A. Papagianni, M. Tsamelashvili, et al. (2006) Induction and long-term treatment with cyclosporine in membranous nephropathy with the nephrotic syndrome. Nephrol Dial Transplant 21 3127-3132.
2. J.D. Adachi, W.G. Benson, J. Brown, et al. (1997) Intermittent etidronate therapy to prevent corticosteroid induced osteoporosis. N Engl J Med 337 382-387.
3. R. Bjorneklett, B.E. Viksc, E. Svarstad, et al. (2007) Long-term risk of cancer in membranous nephropathy patients. Am J Kidney Dis 50 396-403.
4. A.J. Branten, P.W. du Buf-Vereijken, I.S. Klasen, et al. (2005) Urinary excretion of beta 2 microglobulin and IgG predict prognosis in idiopathic membranous nephropathy: A validation study. J Am Soc Nephrol 16 169-174.
5. A.J. Branten, du Buf-Vereijken, M. Vervloet and J.F. Wetzels (2007) Mycophenolate mofetil in idiopathic membranous nephropathy: A clinical trial with comparison to a historical control group treated with cyclophosphamide. Am J Kidney Dis 50 248-256.
6. A.J. Branten, L.J. Reichert, R.A. Koene, et al. (1998) Oral cyclophosphamide versus chlorambucil in the treatment of patients with membranous nephropathy and renal insufficiency. Q J Med 91 359-366.
7. D.C. Cattran, G.B. Appel, L.A. Hebert, et al. (2001) Cyclosporine in patients with steroid resistant membranous nephropathy: A randomized trial. Kidney Int 59 1484-1490.
8. D.C. Cattran, C. Greenwood, S. Ritchie, et al. (1995) A controlled trial of cyclosporine in patients with progressive membranous nephropathy. Canadian Glomerulonephritis Study Group. Kidney Int 47 1130-1135.
9. D.C. Cattran, Y. Pei, C.M. Greenwood, et al. (1997) Validation of a predictive model of idiopathic membranous nephropathy: Its clinical and research implications. Kidney Int 51 901-907.
10. H. Debiec, V. Guigonis, B. Mougenot, et al. (2002) Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies. N Engl J Med 346 2053-2060.
11. F.C. Fervenza, F.G. Cosio, S.B. Ericsson, et al. (2007) Rituximab treatment of idiopathic membranous nephropathy. Kidney Int 73 117-125.
12. The GISEN Group (1997) Randomized placebo-controlled trial of the effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet 349 1857-1863.
13. E. Honkanen, T. Tornroth and C. Gronhagen-Riska (1992) Natural history, clinical course and morphological evolution of membranous nephropathy. Nephrol Dial Transplant 7(Suppl 1), 35-41.
14. V. Jha, A. Ganguli, T.K. Saha, et al. (2007) A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy. J Am Soc Nephol 18 1899-1904.
15. B.J. Laluck Jr. and D.C. Cattran (1999) Prognosis after a complete remission in adult patients with idiopathic membranous nephropathy. Am J Kidney Dis 33 1026-1032.
16. T.L. Nicholas, J. Radhakrishnan and G.B. Appel (2003) Hyperlipidemia and thrombotic complications in patients with membranous nephropathy. Semin Nephrol 23 406-411.
17. M. Praga, V. Barrio, G.F. Juarez, et al. (2007) Tacrolimus mono therapy in membranous nephropathy: A randomized controlled trial. Kidney Int 71 924-930.
18. C. Ponticelli, P. Passerini, M. Salvadori, et al. (2006) A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotrophic hormone in idiopathic membranous nephropathy. Am J Kidney Dis 47 233-240.
19. C. Ponticelli, P. Zucchelli, P. Passerini, et al. (1995) A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. Kidney Int 48 1600-1604.
20. T.J. Rabelink, J.J. Zwaginga, H.A. Koomans, et al. (1994) Thrombosis and hemostasis in renal disease. Kidney Int 46 287-296.
21. P. Ruggenenti, C. Chiurchiu, V. Brusegan, et al. (2003) Rituximab in idiopathic membranous nephropathy: A one-year prospective study. J Am Soc Nephrol 14 1851-1857.
22. A. Schieppati, L. Mosconi, A. Perna, et al. (1993) Prognosis of untreated patients with idiopathic membranous. N Engl J Med 329 85-89.
23. A. Torres, B. Dominguez-Gil, A. Carreno, et al. (2002) Conservative versus immunosuppressive treatment of patients with idiopathic membranous nephropathy. Kidney Int 61 219-227.
24. S. Troyanov, L. Roasio, M. Pandes, et al. (2006) Renal pathology in idiopathic membranous nephropathy: A new perspective. Kidney Int 69 1641-1648.
25. S. Troyanov, C.A. Wall, J.A. Miller, et al. (2004) Idiopathic membranous nephropathy: Definition and relevance of a partial remission. Kidney Int 66 1199-1205.
26. D.C. Wheeler and D.B. Bernard (1994) Lipid abnormalities in the nephrotic syndrome: Causes, consequences, and treatment. Am J Kidney Dis 23 331-346.